DYN
Dyne·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Ample Liquidity
EPS Beats Expectation
Price Hits New High
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DYN
Dyne Therapeutics, Inc.
A biotechnology company developing innovative muscle biology-based therapies for serious muscle diseases and injuries
1560 Trapelo Road, Waltham, Massachusetts 02451
--
Dyne Therapeutics, Inc., was incorporated under the laws of the State of Delaware on December 1, 2017. The company is building a leading muscle disease company dedicated to developing innovative life-changing therapies for patients with genetically driven diseases. The company is leveraging its proprietary FORCE platform to overcome the limitations of current muscle tissue delivery and develop modern oligonucleotide therapies for muscle diseases.
Company Financials
EPS
DYN has released its 2025 Q3 earnings. EPS was reported at -0.76, versus the expected -0.85, beating expectations. The chart below visualizes how DYN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
